Generate Biomedicines (NASDAQ:GENB) Stock Price Up 7.6% – Still a Buy?

Posted by Brenda Bartman on May 12th, 2026

Generate Biomedicines Inc (NASDAQ:GENB – Get Free Report) traded up 7.6% during mid-day trading on Tuesday . The company traded as high as $15.38 and last traded at $15.4630. 33,735 shares were traded during mid-day trading, a decline of 93% from the average session volume of 454,893 shares. The stock had previously closed at $14.37.

Trending Headlines about Generate Biomedicines

Here are the key news stories impacting Generate Biomedicines this week:

Positive Sentiment: HC Wainwright maintained a Buy rating and $25 price target on Generate Biomedicines, which supports the bull case even as it adjusted some quarterly estimates.
Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate for GENB, suggesting slightly better expected performance in that period. Generate Biomedicines Analyst Coverage
Positive Sentiment: The company’s recent price strength may also be helped by the stock trading near its 52-week high, which can attract momentum investors.
Neutral Sentiment: Generate Biomedicines’ institutional holdings page was updated, but no specific buying or selling activity was highlighted, so the impact on the stock is unclear. Institutional Holdings
Negative Sentiment: HC Wainwright cut EPS estimates for several periods, including Q2 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2026 and FY2027, which suggests analysts see higher losses or weaker profitability ahead.
Negative Sentiment: The company also reported a wider-than-expected quarterly loss in its most recent earnings release, which may continue to weigh on sentiment despite the bullish rating.

Analysts Set New Price Targets

A number of brokerages have weighed in on GENB. Morgan Stanley started coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating and a $20.00 price target for the company. HC Wainwright upped their target price on Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday. The Goldman Sachs Group initiated coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price target on the stock. Piper Sandler assumed coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 target price on the stock. Finally, Guggenheim assumed coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They issued a “buy” rating and a $30.00 price target on the stock. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Generate Biomedicines presently has an average rating of “Moderate Buy” and an average target price of $25.00.

Check Out Our Latest Analysis on Generate Biomedicines

Generate Biomedicines Price Performance

The business’s fifty day moving average is $12.68.

Generate Biomedicines (NASDAQ:GENB – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

(Get Free Report)

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.